A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
- Cancer
- Breast Cancer
- HER2-Positive Breast Cancer
Recruiting
- Anyang
- bao-ding-shi
- bei-jing-shi
- Beijing
- chang-chun-shi
- Cheng Du Shi
- Fuzhou
- guang-zhou-shi
- hang-zhou-shi
- Harbin
- Hefei Shi
- Ji Nan Shi
- nan-chang-shi
- nan-ning-shi
- nan-tong-shi
- Nanjing
- ning-bo-shi
- Shenyang
- Shenzhen
- tai-an-shi
- Taiyuan
- tian-jin-shi
- wei-fang-shi
- wu-han-shi
- wu-lu-mu-qi-shi
- Wuhan
- xi-an-shi
NCT05945927 ML44675
Trial Summary
This study is a post-marketing, observational, multicenter, prospective study. It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice.
An Observational Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Second- or Later-Line Therapy in Chinese Patients With HER2 Positive Advanced Breast Cancer
Eligibility Criteria
- Diagnosed with HER2-positive, unresectable locally advanced or metastatic breast cancer before the start of T-DM1 treatment
- Had prior treatment for breast cancer which must contain a taxane and trastuzumab
- Get the treatment of T-DM1 for the first time after diagnosis of breast cancer
- Patients not receiving treatment for HER2-positive breast cancer with T-DM1 according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling
- Has been previously treated with T-DM1 before current clinical visit
- Currently participating in any clinical trials
- Previously participated in any clinical trials investigating anti-HER2 drug within 1 year of the initiation of T-DM1
For the latest version of this information please go to www.forpatients.roche.com